Global RNA-Based Therapeutics Market Overview:
Global RNA-Based Therapeutics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2024-2035, Considering the Base Year As 2025.
Global RNA-Based Therapeutics Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2024-2035, with base year as 2025. This research study of RNA-Based Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the RNA-Based Therapeutics Market:
The RNA-Based Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for RNA-Based Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study RNA-Based Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, RNA-Based Therapeutics market has been segmented into:
RNA Interference (RNAi
By Application, RNA-Based Therapeutics market has been segmented into:
Genetic Disorders and Auto Immune Disorders
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The RNA-Based Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the RNA-Based Therapeutics market.
Top Key Players Covered in RNA-Based Therapeutics market are:
Arrowhead Pharmaceuticals
Arbutus Biopharma Corporation
Benitec Biopharma Inc.
Silence Therapeutics plc
Ionis Pharmaceuticals
Gradalis
Inc.
Biogen
Inc
Alnylam Pharmaceuticals
Inc.
Genzyme (Sanofi)
Sarepta Therapeutics
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: RNA-Based Therapeutics Market Type
4.1 RNA-Based Therapeutics Market Snapshot and Growth Engine
4.2 RNA-Based Therapeutics Market Overview
4.3 RNA Interference (RNAi
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.3.3 RNA Interference (RNAi: Geographic Segmentation Analysis
Chapter 5: RNA-Based Therapeutics Market Application
5.1 RNA-Based Therapeutics Market Snapshot and Growth Engine
5.2 RNA-Based Therapeutics Market Overview
5.3 Genetic Disorders and Auto Immune Disorders
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.3.3 Genetic Disorders and Auto Immune Disorders: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 RNA-Based Therapeutics Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ARROWHEAD PHARMACEUTICALS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 ARBUTUS BIOPHARMA CORPORATION
6.4 BENITEC BIOPHARMA INC.
6.5 SILENCE THERAPEUTICS PLC
6.6 IONIS PHARMACEUTICALS
6.7 GRADALIS
6.8 INC.
6.9 BIOGEN
6.10 INC
6.11 ALNYLAM PHARMACEUTICALS
6.12 INC.
6.13 GENZYME (SANOFI)
6.14 SAREPTA THERAPEUTICS
Chapter 7: Global RNA-Based Therapeutics Market By Region
7.1 Overview
7.2. North America RNA-Based Therapeutics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 RNA Interference (RNAi
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Genetic Disorders and Auto Immune Disorders
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe RNA-Based Therapeutics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 RNA Interference (RNAi
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Genetic Disorders and Auto Immune Disorders
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe RNA-Based Therapeutics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 RNA Interference (RNAi
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Genetic Disorders and Auto Immune Disorders
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific RNA-Based Therapeutics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 RNA Interference (RNAi
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Genetic Disorders and Auto Immune Disorders
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa RNA-Based Therapeutics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 RNA Interference (RNAi
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Genetic Disorders and Auto Immune Disorders
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America RNA-Based Therapeutics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 RNA Interference (RNAi
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Genetic Disorders and Auto Immune Disorders
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
RNA-Based Therapeutics Scope:
|
Report Data
|
RNA-Based Therapeutics Market
|
|
RNA-Based Therapeutics Market Size in 2025
|
USD XX million
|
|
RNA-Based Therapeutics CAGR 2025 - 2032
|
XX%
|
|
RNA-Based Therapeutics Base Year
|
2024
|
|
RNA-Based Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Arrowhead Pharmaceuticals, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Silence Therapeutics plc, Ionis Pharmaceuticals, Gradalis, Inc., Biogen, Inc, Alnylam Pharmaceuticals, Inc., Genzyme (Sanofi), Sarepta Therapeutics.
|
|
Key Segments
|
By Type
RNA Interference (RNAi
By Applications
Genetic Disorders and Auto Immune Disorders
|
